{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:34:48Z","timestamp":1768908888339,"version":"3.49.0"},"reference-count":62,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"grants-in-aid from the Ministry of Health, Labor, and Welfare, Japan"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,2,4]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both first-line and salvage therapies. Specifically, in the Japanese single-arm, phase II trial, the MERIT trial, nivolumab, an antiprogrammed cell death 1 (PD-1) antibody showed favorable efficacy when used as a salvage therapy. Currently, multiple ICI monotherapy or combination therapy trials have been conducted, which could provide further evidence. Among available ICIs, the anti-PD-1 antibody is promising for unresectable MPM, despite the limited efficacy of anti-CTLA4 monotherapy. Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM.<\/jats:p>","DOI":"10.1136\/jitc-2019-000461","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T07:24:22Z","timestamp":1582615462000},"page":"e000461","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02784171","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02899195","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02899299","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03063450","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03063450","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02399371","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Katsuyuki","family":"Hotta","sequence":"first","affiliation":[{"name":"Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukazu","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Medicine, Okayama Rosai Hospitalosai Hospital, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"2025100311104533000_8.1.e000461.1","doi-asserted-by":"publisher","DOI":"10.1179\/2049396712Y.0000000016"},{"key":"2025100311104533000_8.1.e000461.2","unstructured":"Ministry of the environment government of Japan. Available: http:\/\/www.env.go.jp\/air\/asbestos\/registration\/ [Accessed 15 Aug 2019]."},{"key":"2025100311104533000_8.1.e000461.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.42"},{"key":"2025100311104533000_8.1.e000461.4","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2025100311104533000_8.1.e000461.5","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-019-0613-x","article-title":"Use of immune checkpoint inhibitors in mesothelioma","volume":"20","author":"Forde","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"2025100311104533000_8.1.e000461.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70257-2"},{"key":"2025100311104533000_8.1.e000461.7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus report of the 2015 Weinman International Conference on mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025100311104533000_8.1.e000461.8","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-009-9357-4"},{"key":"2025100311104533000_8.1.e000461.9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/modpathol.2017.108","article-title":"Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma","volume":"31","author":"Vivero","year":"2018","journal-title":"Mod Pathol"},{"key":"2025100311104533000_8.1.e000461.10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5858\/arpa.2017-0365-RA","article-title":"Malignant mesothelioma and its non-asbestos causes","volume":"142","author":"Attanoos","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"2025100311104533000_8.1.e000461.11","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0804"},{"key":"2025100311104533000_8.1.e000461.12","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520"},{"key":"2025100311104533000_8.1.e000461.13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025100311104533000_8.1.e000461.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612074113"},{"key":"2025100311104533000_8.1.e000461.15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jtho.2018.11.006","article-title":"Does chromothripsis make mesothelioma an immunogenic cancer?","volume":"14","author":"Carbone","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025100311104533000_8.1.e000461.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"2025100311104533000_8.1.e000461.17","doi-asserted-by":"publisher","DOI":"10.1038\/nri727"},{"key":"2025100311104533000_8.1.e000461.18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090331"},{"key":"2025100311104533000_8.1.e000461.19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"2025100311104533000_8.1.e000461.20","doi-asserted-by":"publisher","DOI":"10.1038\/nm730"},{"key":"2025100311104533000_8.1.e000461.21","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486"},{"key":"2025100311104533000_8.1.e000461.22","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101324"},{"key":"2025100311104533000_8.1.e000461.23","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2025100311104533000_8.1.e000461.24","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025100311104533000_8.1.e000461.25","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","article-title":"Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages","volume":"11","author":"Ch\u00e9n\u00e9","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025100311104533000_8.1.e000461.26","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm091"},{"key":"2025100311104533000_8.1.e000461.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"2025100311104533000_8.1.e000461.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2025100311104533000_8.1.e000461.29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"key":"2025100311104533000_8.1.e000461.30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025100311104533000_8.1.e000461.31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025100311104533000_8.1.e000461.32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (initiate): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025100311104533000_8.1.e000461.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"2025100311104533000_8.1.e000461.34","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177"},{"key":"2025100311104533000_8.1.e000461.35","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14712598.2019.1606209","article-title":"Immune checkpoint inhibition for the treatment of mesothelioma","volume":"19","author":"Nowak","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2025100311104533000_8.1.e000461.36","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jtho.2018.06.011","article-title":"Scientific advances and new frontiers in mesothelioma therapeutics","volume":"13","author":"Mutti","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025100311104533000_8.1.e000461.37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.109"},{"key":"2025100311104533000_8.1.e000461.38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh476"},{"key":"2025100311104533000_8.1.e000461.39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/JTO.0b013e31802bb010","article-title":"Long-Standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer","volume":"2","author":"Hotta","year":"2007","journal-title":"J Thorac Oncol"},{"key":"2025100311104533000_8.1.e000461.40","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22478"},{"key":"2025100311104533000_8.1.e000461.41","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt128"},{"key":"2025100311104533000_8.1.e000461.42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10147-015-0860-1","article-title":"Short-Term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama lung cancer Study Group trial 1201","volume":"21","author":"Ninomiya","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"2025100311104533000_8.1.e000461.43","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv065"},{"key":"2025100311104533000_8.1.e000461.44","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.resinv.2019.04.004","article-title":"Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: a sub-analysis of data from the two Okayama lung cancer Study Group prospective feasibility studies","volume":"57","author":"Nishii","year":"2019","journal-title":"Respir Investig"},{"key":"2025100311104533000_8.1.e000461.45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"2025100311104533000_8.1.e000461.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"2025100311104533000_8.1.e000461.47","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025100311104533000_8.1.e000461.48","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and future management of malignant mesothelioma: a consensus report from the National cancer Institute thoracic malignancy Steering Committee, International association for the study of lung cancer, and mesothelioma applied research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025100311104533000_8.1.e000461.49","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/j.jtho.2018.08.276","article-title":"OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result","volume":"13","author":"Nowak","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025100311104533000_8.1.e000461.50","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1016\/j.cllc.2018.05.001","article-title":"A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol","volume":"19","author":"Fujimoto","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2025100311104533000_8.1.e000461.51","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of clinical oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025100311104533000_8.1.e000461.52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70056-2"},{"key":"2025100311104533000_8.1.e000461.53","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025100311104533000_8.1.e000461.54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0103"},{"key":"2025100311104533000_8.1.e000461.55","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1B trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025100311104533000_8.1.e000461.56","doi-asserted-by":"crossref","unstructured":"Desai A , Karrison T , Rose B , et al . Phase II trial of pembrolizumab (NCT02399371) in previously treated malignant mesothelioma: final analysis, in IASLC (ED). 19th IASLC World Conference on Lung Cancer Toronto, Canada, 2018.","DOI":"10.1016\/j.jtho.2018.08.277"},{"key":"2025100311104533000_8.1.e000461.57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1B results from the javelin solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100311104533000_8.1.e000461.58","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4"},{"key":"2025100311104533000_8.1.e000461.59","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2025100311104533000_8.1.e000461.60","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (determine): a multicentre, international, randomised, double-blind, placebo-controlled phase 2B trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025100311104533000_8.1.e000461.61","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2025100311104533000_8.1.e000461.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2019-000461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:10:57Z","timestamp":1759515057000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,24]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/jitc-2019-000461"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2019-000461","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}